Subject of the day
TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $329.00M | +199.6% | |
| Operating income | $123.32M | +194.1% | |
| Net income | $23.38M | +84.5% | |
| Cash from ops | -$31.41M | — |
$47.94
▼ -1.56 (-3.2%)
| 52w hi | $59.06 |
|---|---|
| 52w lo | $26.94 |
| Vol | 2.67M |
| As of | Aug 13 |
Our score +0.50
| Short | +0.40 |
|---|---|
| Medium | +0.66 |
| Long | +0.36 |
computed 2026-08-13
TG Therapeutics, Inc.
Healthcare · Biotechnology
| Market cap | $7.34B |
|---|---|
| Enterprise value | $7.22B |
| Trailing P/E | 17.50x |
| Forward P/E | 16.17x |
| EV / EBITDA | 52.94x |
| P / S (ttm) | 9.18x |
| Profit margin | 55.2% |
| Return on equity | 100.3% |
| Revenue growth | +70.3% |
| Earnings growth | -70.6% |
| Debt / equity | 124.89 |
| Beta vs SPX | 0.72 |
|---|---|
| Corr SPX | 0.22 |
| Annual vol | 53.8% |
| Annual ret | +58.0% |
| Sharpe | 1.08 |
| Max DD | -42.0% |
Window: 504 trading days (504 obs)
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.17 | |
| Sector | +0.12 | |
| Technical | +0.38 | |
| Earnings | +0.00 | |
| Sentiment | -0.13 |
macro × 1.00 · 2026-08-13
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Aug 13 | $49.70 | $49.70 | $47.53 | $47.94 | 2.67M |
| Aug 12 | $50.00 | $50.54 | $49.34 | $49.50 | 2.02M |
| Aug 11 | $49.29 | $50.35 | $49.00 | $49.90 | 1.50M |
| Aug 10 | $49.26 | $50.00 | $48.50 | $49.16 | 1.91M |
| Aug 7 | $49.96 | $50.19 | $49.11 | $49.76 | 1.77M |